Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Exelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which beat the Zacks Consensus Estimate of 51 cents. The company registered ...

The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.

The FDA has granted Fast Track designation to amezalpat (TPST-1120) for the treatment of patients with hepatocellular carcinoma.

Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from ...

Black women are more likely to die from it. There are more than 600,000 survivors of endometrial cancer in the US today. Our team is made up of doctors and oncology certified nurses with deep ...

The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds ...

CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...

Hundreds of a people who have chronic liver disease are being helped by an NHS trust's service that helps them attend vital ...